"This is the first time we've seen improvement in fibrosis that was observed in participants with compensated cirrhosis due ...

Though there are very few characters in MASH who aren't beloved by audiences and critics, these individuals rise to the top ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition.

This local sensation mashes up pop and rock hits with a full brass section, turning every show into a high-energy singalong.